Hylander, I am going to assume that “they”
Post# of 36537
I am going to assume that “they” in your question is the buyer Bio & Med Tech.
1st question:
Bio (Stalking Horse) is buying only NuGenerex and Olaregen.
Bio will own NuGenerex and Olaregen free and clear of any debt and future litigation or creditor claims.
Generex get $1,500,000 cash.
The creditors of the Generex bankruptcy get to fight over the $1,500,000 cash.
2nd question:
Bio will now own 64,153,151 shares of NuGenerex instead of Generex.
Bio now becomes the new “holding” company.
Think of it as a name change Bio instead of Generex, nothing else changes.
But instead of Joe calling the shots, Bio will.
So, what will Bio do?
If they follow thru with the IPO Joe envisioned, then we could see real pps value.
3rd question:
Selling NGIO does nothing for Generex pps since the $1.5 mil will be used to pay creditors.
Bio is not acquiring any GNBT shares, Generex is being liquidated.
As for all the other companies listed under Generex in the Doc 40 filing https://investorshangout.com/post/view?id=6484085, they had no assigned value. Maybe they exist in name only. If these “divisions” have any true value, they will be auctioned off (probably for next to nothing) and the proceeds will be added to the $1.5 mil for the creditors to fight over.